Substituted pyridine spleen tyrosine kinase (SYK) inhibitors

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Merck Sharp & Dohme Corp., , Merck Canada Inc. patent solves the following problem:

Spleen Tyrosine Kinase (SYK) is a protein tyrosine kinase described as a key mediator of immunoreceptor signaling a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptor and the B-cell receptor, is important for allergic diseases, and antibody-mediated autoimmune diseases and thus pharmacologically interfering SYK conceivably treat these diseases.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp., , Merck Canada Inc.’s patent US 9376418 B2 deals with Substituted pyridine spleen tyrosine kinase (SYK) inhibitors.
invention provides certain substituted Pyridines of Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, P3, R4, rcy, CY, and t as described here. invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated spleen tyrosine kinase (SYK) kinase.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Dry powder pharmaceutical composition for inhalation

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Daiichi Sankyo Company, Limited patent solves the following problem:

Japanese Patent No. 3209946 (Patent Document 1) discloses compounds with neuraminidase inhibitory activity, including the compound represented by formula (I) shown below. The compound represented by formula (I) have excellent neuraminidase inhibitory activity and is expected to be useful as a drug for treating and preventing influenza virus infection. Japanese Patent No. 4205314 (Patent Document 2) revealed a concentration of the compound represented by formula (I) can remain on for a long time in the respiratory tissues like lung (Patent Document 2).

Our analysis of this patent is as follows:

Daiichi Sankyo Company, Limited’s patent US 9339487 B2 deals with Dry powder pharmaceutical composition for inhalation.
There was a dry powder pharmaceutical composition for inhalation is useful for preventing and / or treating influenza virus infections included as a medicinal component of a compound represented by formula (I): and optionally a compound represented by formula (II): a pharmacologically acceptable salt thereof, or a hydrate thereof.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Nutritional composition with probiotics

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The N.V. Nutricia patent solves the following problem:

Infants without intestinal flora at birth. As a result of contact with the mother during birth and subsequent feeding with human milk or formula milk, the intestinal flora rapidly. During the development, the intestinal flora is still immature and normal activities are weak. Human milk-fed infants are less afflicted by infections or diseases than formula-fed infants. Thus, human milk-fed children have less gastro-intestinal infections in terms of incidents and the duration, less atopic diseases such as allergies, eczema, less colics and cramps, and less constipation than formula-fed infants. pain came later in life, such as childhood obesity, diabetes, and asthma are related to the kind of feeding during the early stages of life, with human milk-fed infants for good .

Our analysis of this patent is as follows:

N.V. Nutricia’s patent US 9314047 B2 deals with Nutritional composition with probiotics.
A composition comprising Bifidobacterium breve, a non-digestible saccharide A and a non-digestible saccharide B, optionally with Lactobacillus paracasei and the use of said composition for the treatment and / or prevention of gastro-intestinal disorders, immune disorder and / or endocrine disorder.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Information environment map

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Domo, Inc. patent solves the following problem:

Our analysis of this patent is as follows:

Domo, Inc.’s patent US 9299170 B1 deals with Information environment map.
Information presented on a map like a map of the city, with the relevant information to different groups of neighborhoods. Such a display method takes advantage of spatial cognition to provide an organizational and presentational devices that users can more easily remember where to look and find the right information. Metadata, notifications, and / or other auxiliary information may be presented with or cast on the data itself.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Aminopyrimidines as Syk inhibitors

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Merck Sharp & Dohme Corp. patent solves the following problem:

Spleen Tyrosine Kinase (SYK) is a protein tyrosine kinase described as a key mediator of immunoreceptor signaling a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptor and the B-cell receptor, is important for allergic diseases, and antibody-mediated autoimmune diseases and thus, pharmacologically interfering with SYK conceivably treat these diseases.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp.’s patent US 9290490 B2 deals with Aminopyrimidines as Syk inhibitors.
The present invention provides new pyrimidine amines of formula I are potent inhibitor of spleen tyrosine kinase, and is useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis and cancer.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Dosage and formulation

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Almirall, S.A. patent solves the following problem:

Aclidinium bromide is 3 (R) – (2-hydroxy-2,2-dithien-2-ylacetoxy) -1- (3-phenoxypropyl) -1-azoniabicyclo [2.2.2] octane bromide, described in, for example WO 0104118. Although this compound is known as a long-acting anticholinergic useful in the treatment of respiratory diseases, the optimal dose was not disclosed.

Our analysis of this patent is as follows:

Almirall, S.A.’s patent US 9254262 B2 deals with Dosage and formulation.
The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder in a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Cross-environment application compatibility for single mobile computing device

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Z124 patent solves the following problem:

This relates generally to the field of mobile environments Computing, and especially to support many user environment through the use of multiple operating systems on a single mobile computing device.

Our analysis of this patent is as follows:

Z124’s patent US 9160796 B2 deals with Cross-environment application compatibility for single mobile computing device.
A seamless cross-around workflow given a multi-operating system environment Computing. The multi-operating system computing environments may include a mobile operating system and a desktop operating system running simultaneously and independently on a mobile device Computing. Two or more application programs, running the operating system independent of user interaction with the state information including user data, user settings, and / or application context information. Interaction with the state information may be shared for the applications used primarily to access and edit the user's local content as well as applications that communicate with a remote server or access and navigate other remote content ( for example, Internet-based application, browser, etc.). The mobile computing device may be a smartphone running the Android mobile operating system and a complete desktop Linux distribution on a modified Android kernel.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method for treating cancer using an antibody that inhibits notch4 signaling

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The The Regents Of The University Of Michigan patent solves the following problem:

Cancer remains the number two cause of death in this country, resulting in more than 500,000 deaths each year. Despite progress in detection and treatment, cancer mortality remains high. Despite remarkable progress in understanding the molecular basis of cancer, this knowledge has not yet translated into effective therapeutic strategies.

Our analysis of this patent is as follows:

The Regents Of The University Of Michigan’s patent US 9089556 B2 deals with Method for treating cancer using an antibody that inhibits notch4 signaling.
invention provides methods for treating cancer by administering to a patient having a solid tumor in a therapeutically effective amount of an antibody against Delta-like ligand 4 (Dll4) or others notch road components. The strong tumor may contain strong tumor stem cells.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

System and method for kernel rootkit protection in a hypervisor environment

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Mcafee, Inc. patent solves the following problem:

In the field of computer network security has become more important and complicated in today's society. about Computer network configured for virtually every business or organization, often with many interconnected computer (for example, the end user computers, laptops, servers, printing devices, etc.). Moreover, the cloud service providers (and other organizations that run multiple applications and operating systems) may use hypervisor technology to run on various different guest operating systems simultaneously on a host device. A hypervisor is a computer software / hardware platform virtualization software that allows multiple operating systems to run on a host computer simultaneously. security threat may come from outside and internally in hypervisor environment. These threats to the hypervisor environment present further challenges for IT administrators.

Our analysis of this patent is as follows:

Mcafee, Inc.’s patent US 9069586 B2 deals with System and method for kernel rootkit protection in a hypervisor environment.
A system and method for protection rootkit in a hypervisor environment includes modules for creating a soft whitelist entries corresponding to each visitor flesh page to a guest operating system in a hypervisor environment, where each entry is a copy of the page to the corresponding page guest flesh, creating a page fault when a process tries to access a page visitor flesh, and teach the process corresponding page article. If the page fault is a data page faults, the method includes hard page faults, and marking a page table entry corresponding to the guest kernel pages as non-executable and writeable. If the page is wrong is a wrong instruction page, the method involves marking a page table entry corresponding to the page flesh guest as read-only. Redirecting changing a page frame number in a shadow page table hypervisor to teach the corresponding duplicate pages.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Cross-environment communication using application space API

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Z124 patent solves the following problem:

This relates generally to the field of mobile environments Computing, and especially to support many user environment through the use of multiple operating systems on a single mobile computing device.

Our analysis of this patent is as follows:

Z124’s patent US 9063798 B2 deals with Cross-environment communication using application space API.
A mobile computing devices with a mobile operating systems and desktop operating systems running simultaneously and independently on a shared grain without virtualization. The mobile operating system provides a mobile user experience as the desktop operating system provides a complete desktop user experience when the mobile computing device is docked to a secondary terminal environment. Applications in desktop operating systems to communicate with applications and services in the mobile operating system with a framework cross-communication environment. The cross-premises communication structure may include application programming interfaces through which categories of applications communicate across a multiple computing environment operating system through category-specific calls remote communication. The mobile computing device may be a smartphone running the Android mobile operating system and a complete desktop Linux distribution on a modified Android kernel.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.